Watson to open New Jersey R&D center

Wednesday, February 1, 2012 03:37 PM

Watson Pharmaceuticals is planning a global R&D technology center in North Brunswick, N.J. The company has signed a lease for a 32,000-square-foot facility at the Economic Development Authority's Technology Center of New Jersey, a 50-acre complex consisting of lab, production and office space. Watson intends to initially invest approximately $4.5 million in outfitting the new facility.

Watson will immediately retrofit approximately 19,000 square feet of space for product development and analytical laboratories.  The remaining 13,000 square feet will accommodate future expansion.  The facility, which is expected to be completed this spring, will employ approximately 50 scientists, chemists, engineers and support staff. 

"The location of the new Global R&D Technology Center will enable Watson to leverage our proximity to such educational centers of excellence as Rutgers University,” said Paul Bisaro, president and CEO of Watson. “This will enable Watson to establish collaborations with university departments including pharmaceutics, chemistry and engineering and permit us to benefit from the talent pool in the heart of the pharmaceutical industry of New Jersey.” 

The new center will become Watson's state-of-the-art facility for developing generic pharmaceutical products, in particular for inhalation technology and respiratory products, with the ability to conduct formulation development and analytical testing, Bisaro said.

In early 2010, Watson relocated its global corporate headquarters to Parsippany, N.J., in a facility designed to support its global expansion and ultimately employ as many as 500 people.

With its new location, Watson joins companies including Merial, Chromocell and Rutgers Technology Center.

Share:          
CWWeekly

March 23

Industry welcomes FDA draft guidance outlining the use of electronic Informed Consent for trials

Apple launches ResearchKit platform to tap millions of iPhone users to enroll in observational studies using apps

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

March

Novo Nordisk, Takeda, Servier, Celgene among top sponsors
New gains seen from patient- and site-centric initiatives

Patient reported outcomes take center stage
FDA combining PROs, clinical outcomes in its approval decisions

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

February

Study grants market breaks $13 billion
Volume of clinical activity rising while growth in grant spending slows

Revisiting eClinical Technology Solutions Adoption
While use of established solutions grows, sponsors hesitate on newer tools

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs